1) Successfully developed ART352-L, a liposomal formulation of recombinant human WNT3A protein, that is applied ex vivo, to harvested autologous bone graft (autograft) to enhance the osteogenic ...

Maggie, a former marathon runner, was diagnosed in 2006 with multiple sclerosis—a disease whose symptoms progress from relatively mild, such as the limb numbness she experiences, to severe, such as ...

Las reuniones de la CFAOC están organizadas por la Oficina del Contralor del Estado. A continuación, se incluye una copia de la agenda publicada en https://www.sco ...

There is no shortage of myths and misconceptions when it comes to stem cell research and regenerative medicine. Here we address the most common concerns. If you have more questions that aren’t ...

Retinal degeneration represents a group of blinding diseases that are increasingly impacting the health and well being of Californians. It is estimated that by 2020, over 450,000 Californians will ...

have the ability to divide and create an identical copy of themselves, a process called self-renewal; and can also divide to form cells that mature into cells that make up every type of tissue and ...

Get the latest CIRM news, meetings and funding opportunities delivered straight to your inbox.

Solid tumors include cancers of the brain, ovary, breast, colon and other tissues. Many people believe that one quality solid tumors share is a reliance on cancer stem cells. These cancer stem cells ...

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Deborah K. Armstrong Johns Hopkins University Ovarian, Breast Cancer and Gynecologic Cancer Clinical Trials; Genetics of Familial Breast and Ovarian Cancer ...

San Francisco, CA – California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM) today approved $150 million in new funding to help move promising stem cell-based therapies ...